Lupin intros generic Lodosyn
Lupin has launched its generic of Lodosyn (carbidopa) tablets. The company had previously received approval from the Food and Drug Administration for the generic, which is indicated to treat symptoms associated with Parkinson's disease alongside carbidopa-levodopa or levodopa.
Lupin's generic Lodosyn will be available in 25-mg dosage strength. The product has a market size of roughly $17.4 million for the 12 months ended January 2018, according to IQVIA data.
Lupin's generic Lodosyn will be available in 25-mg dosage strength. The product has a market size of roughly $17.4 million for the 12 months ended January 2018, according to IQVIA data.